Evidence map›Paper›PMID 38111583›Full record

ArticleFrontiers in immunology2023

Case Report: Long-term metabolic response of metastatic uveal melanoma to pembrolizumab on FDG-PET/CT despite a serial pseudoprogressions phenomenon.

Karim Amrane, Coline Le Meur, Philippe Thuillier, Jacques Dzuko Kamga, Pierre Alemany, Frederic Chauvelot, Clémence Niel, Alex Bellange, Ronan Abgral

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 69% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Complex immunotherapy-mediated response patterns depicted on serialAsia Oceania journal of nuclear medicine & biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Karim Amrane *Department of Oncology, Centre Hospitalier des Pays de Morlaix, Morlaix, France.
Coline Le Meur *Department of Radiotherapy, University Hospital of Brest, Brest, France.
Philippe ThuillierInserm, UMR1227, Lymphocytes B et Autoimmunité, Univ Brest, Inserm, LabEx Immunotherapy-Graft-Oncology (IGO), Brest, France.
Jacques Dzuko KamgaDepartment of Nuclear Medicine, University Hospital of Brest, Brest, France.
Pierre AlemanyDepartment of Pathology, Ouestpathology Brest, Brest, France.
Frederic ChauvelotDepartment of Onco-pharmacy, Centre Hospitalier des Pays de Morlaix, Morlaix, France.
Clémence NielDepartment of Oncology, Centre Hospitalier des Pays de Morlaix, Morlaix, France.
Alex BellangeDepartment of Oncology, Centre Hospitalier des Pays de Morlaix, Morlaix, France.
Ronan Abgral *Department of Nuclear Medicine, University Hospital of Brest, Brest, France.
Centre Hospitalier Régional Universitaire de Brest · FRCentre Hospitalier des Pays de Morlaix · FRUniversité de Bretagne Occidentale · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uveal melanoma (UV) is a rare and aggressive melanoma with poor 1-year survival. up to 50% of UV patients develop metastases, mainly to the liver. Here, the authors present a 2-deoxy-2-[

Indexed as

MelanomaAged, 80 and overAntibodies, Monoclonal, HumanizedFluorodeoxyglucose F18HumansPositron-Emission TomographyPositron Emission Tomography Computed TomographyUveal MelanomaUveal NeoplasmsAntibodies, Monoclonal, HumanizedFluorodeoxyglucose F18pembrolizumabFDG-PETimmune checkpoint inhibitionpembrolizumabpseudoprogressionuveal melanoma

Identifiers

PMID38111583
PMCPMC10725954
OpenAlexW4389303713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.